Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Summary
    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bayer Files for U.S., EU Approval of Aliqopa/Rituximab Combo

06/21/2021 | 09:26am EDT

By Colin Kellaher

Bayer AG on Monday said it has filed for U.S. and European expanded approval of its cancer drug Aliqopa in combination with rituximab, a drug used to treat certain types of cancer and rheumatoid arthritis.

The Leverkusen, Germany, chemical and pharmaceutical company said it is seeking U.S. Food and Drug Administration approval of the combination in relapsed indolent B-cell non-Hodgkin's lymphoma.

The company said it also has filed for European Medicines Agency approval for the treatment of relapsed marginal zone lymphoma, a subtype of indolent B-cell non-Hodgkin's lymphoma.

Bayer in April said a Phase III study showed a significant progression-free survival benefit for the combination in patients with relapsed indolent non-Hodgkin's lymphoma.

The FDA in 2017 approved Aliqopa for adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

06-21-21 1126ET

All news about BAYER AG
07/30GLOBAL MARKETS LIVE : Caterpillar, Chevron, Robinhood, Bayer, Gilead Sciences...
07/30EUROPEAN MIDDAY BRIEFING : Stocks Fall as -2-
DJ
07/30EMEA MORNING BRIEFING : Stocks Set to Fall After -2-
DJ
07/29BAYER AG : Receives a Buy rating from Bernstein
MD
07/29Materials Up After GDP Report -- Materials Roundup
DJ
07/29BAYER : to Earmark $4.5 Billion for Potential Roundup Litigation Claims
MT
07/29Bayer posts additional $4.5 billion provision for Roundup litigation
RE
07/29Bayer to Set Aside $4.5 Billion in Provisions for Roundup Case; To Petition U..
DJ
07/29BAYER AG : UBS gives a Buy rating
MD
07/28BAYER : Monsanto told to pay teachers $185M over chemical exposure
AQ
More news
Financials
Sales 2021 41 461 M 49 207 M 49 207 M
Net income 2021 3 600 M 4 273 M 4 273 M
Net Debt 2021 38 636 M 45 855 M 45 855 M
P/E ratio 2021 14,6x
Yield 2021 4,03%
Capitalization 49 406 M 58 607 M 58 637 M
EV / Sales 2021 2,12x
EV / Sales 2022 2,00x
Nbr of Employees 99 329
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 50,29 €
Average target price 64,67 €
Spread / Average Target 28,6%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BAYER AG4.43%58 607
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY44.22%221 348